Marizyme, which is developing a portfolio of medical devices for cardiac surgery, CKD, and pet health, filed on Monday with the SEC to raise up to $17 million in a Nasdaq uplisting. The company currently trades on the OTC under the symbol MRZM with a market value of $59 million.
Marizyme is focused on developing three medical technology platforms: DuraGraft, a one-time intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure; MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease (CKD) assessment; and its Krillase protein enzyme, which provides therapeutics for wound healing, thrombosis, and pet health. In 2022, the company plans to focus on achieving FDA approval of DuraGraft as a medical device for coronary bypass artery graft, advance its MATLOC 1 CKD point-of-care device through the filing of an FDA 510(k) application, and advance its Krillase technology through a planned animal study.
The Jupiter, FL-based company was founded in 2007 and plans to list on the Nasdaq under the symbol MRZM. Univest Securities is the sole bookrunner on the deal. No pricing terms were disclosed.
